Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolve 301: RMC-6236 vs docetaxel in previously treated RAS-mutant NSCLC
jRCT2031250204Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Sep 2025
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of daraxonrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Revolution Medicines. Primary endpoints: Progression-free survival in RAS (G12X-C) population and Overall survival in RAS (G12X-C) population. Started Sep 2025; status: recruiting.
02
Drugs
daraxonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250204.